A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics

• DOI: 10.1016/j.omto.2022.12.002
• Publication Date: 2022-12-07T07:10:27Z
• Authors: Sihao Zhu; Ziyuan Li; Dongye Zheng; Yue Yu; Jing Xiang; Xiao Ma; Dongqing Xu; Jiajun Qiu; Ziyu Yang; Zhiyi Wang; Jun Li; Hongfang Sun; Weiqiang Chen; Xiangxi Meng; Yanye Lu; Qiushi Ren
• Keywords: 0301 basic medicine; theranostics; 0303 health sciences; 03 medical and health sciences; angiogenesis inhibition; microRNA delivery; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Original Article; homologous targeting; RC254-282; 3. Good health; microRNA therapeutics

Endogenous microRNAs (miRNA) in tumors are currently under exhaustive investigation as potential therapeutic agents for cancer treatment. Nevertheless, RNase degradation, inefficient and untargeted delivery, limited biological effect, unclear side effects remain unsettled issues that frustrate clinical application. To address this, a versatile targeted delivery system multiple diagnostic should be adapted miRNA. In this study, we developed membrane-coated PLGA-b-PEG DC-chol nanoparticles (m-PPDCNPs) co-encapsulating doxorubicin (Dox) miRNA-190-Cy7. Such showed low biotoxicity, high loading efficiency, superior targeting ability. Systematic of m-PPDCNPs mouse models exceptionally specific tumor accumulation. Sustained release miR-190 inhibited angiogenesis, growth, migration by regulating large group angiogenic effectors. Moreover, also enhanced the sensitivity Dox suppressing TGF-β signal colorectal cell lines models. Together, our results demonstrate stimulating promising nanoplatform theranostics.